NCT06597734

A Phase 2 Study Evaluating Olutasidenib in Combination With Hypomethylating Agents in Patients With IDH1-mutated Higher-risk Myelodysplastic Syndromes, Chronic Myelomonocytic Leukemia, or Advanced Myeloproliferative Neoplasm

WITHDRAWNPHASE2INTERVENTIONAL

Trial Details

Start: 2025-01-28Est. Completion: 2026-06-11

Enrollment target: 0 participants

Other microbiome trials you might be interested in

211At-BC8-B10 Followed by Donor Stem Cell Transplant in Treating Patients With Relapsed or Refractory High-Risk Acute Leukemia or Myelodysplastic SyndromePhase 1Recruiting

Acute Lymphoblastic Leukemia in RemissionAcute Myeloid Leukemia Arising From Previous Myelodysplastic SyndromeAcute Myeloid Leukemia in RemissionChronic Myelomonocytic LeukemiaMyelodysplastic Syndrome With Excess BlastsRecurrent Acute Lymphoblastic LeukemiaRecurrent Acute Myeloid LeukemiaRefractory Acute Lymphoblastic LeukemiaRefractory Acute Myeloid LeukemiaRecurrent Mixed Phenotype Acute LeukemiaRefractory Mixed Phenotype Acute LeukemiaHematopoietic and Lymphoid Cell Neoplasm

This phase I/II trial studies the side effects and best dose of a radioactive agent linked to an antibody (211At-BC8-B10…

Apply or Learn More on ClinicalTrials.gov

MicrobiomeTrials does not provide medical advice. Always consult your doctor before joining a clinical trial.